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Lymphocyte adhesion molecules in T cell· mediated lysis of human 
kidney cells. The complementary adhesion molecules LFA-I (CDlIa, 
IS)/ICAM-l (CD54) and LFA-2 (CD2)/LFA-3 (CD58) have been shown 
to be important in T cell interaction with lymphoid target cells. The role 
of these ligand pairs in cytotoxicity against somatic cells is less well 
established. While LFA-3 is expressed by all cells in the kidney, 
ICAM-I expression is low in normal kidneys but is increased in allograft 
rejection. An in vitro cytotoxicity assay was used to examine the 
relative importance of the two adhesion ligands in immune damage 
against kidney cells in rejection. HLA-A2 specific cytotoxic T lympho-
cyte (CTL) recognition of cultured human kidney cells (HKC), of 
predominantly renal tubular cell origin, was studied. Immunofluores-
cence studies showed that both induced and uninduced HKC target 
cells expressed ICAM-I, MHC class I and LFA-3, but only MHC class 
I and class II antigens and ICAM-l were significantly upregulated by 
cytokine induction. Effector cells expressed LF A-I and LFA-2 but little 
or no ICAM-l and LFA-3. Cytokine induction of ICAM-I expression 
on HKC target cells increased their susceptibility to lysis. Monoclonal 
antibody against ICAM-I or LFA-I produced the greatest inhibition of 
HKC lysis, and their effects were not additive. Antibody against LFA-2 
(CD2) or LFA-3 also produced significant inhibition, but to a lesser 
degree, and no additive effect was found . The combination of antibody 
against both adhesion bridges almost completely abrogated lysis of 
HKC target cells, and this was as effective as a combination of 
antibodies that blocked binding by the T cell receptor to target cell class 
I MHC. These results suggest that ICAM-I, not expressed on normal 
kidney cells in vivo, but significantly induced in allograft rejection, may 
playa significant role in increasing the susceptibility of kidney cells to 
immune lysis, and modulation of these interactions may protect the 
graft from rejection. 
The mediation of cytotoxicity by T cells has two essential 
steps, conjugate formation, in which the T cell binds to the 
target cell, and activation of the T cell to deliver the "lethal 
hit", where the target cell is programmed for lysis [1]. The 
binding of effector T cells to their targets involves several 
distinct cell surface molecular interactions [2]. The recognition 
of specific antigen involves T cell receptor binding to antigen in 
the context of self-MHC or as allo-MHC [3]. These interactions 
are directly facilitated by coreceptors, either CD4 or CDS, 
which bind directly to invariant portions of class II and class I 
MHC, respectively [4]. In addition leukocyte-lymphocyte ad-
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hesion molecules have been shown to be important, including 
LFA-I (COlla, CDlS), a member of the integrin superfamily 
and ICAM-l (CD54) , LFA-2 (CD2) and LFA-3 (CD5S), mem-
bers of the immunoglobulin supergene family [5]. 
LF A-I, which is present on almost all leukocytes [6], forms 
an adhesion bridge with ICAM-I [7, S]. LFA-2 (CD2), which is 
present only on T cells and NK cells [9], interacts with LFA-3, 
which is expressed by nearly all somatic cells [10, 11]. The 
importance of these receptor-ligand pairs was demonstrated by 
the capacity of monoclonal antibodies to inhibit T cell adhesion 
to and cytolysis of lymphocyte target cells [7, S, 12-15]. The 
role of these adhesion molecule interactions in the lysis of 
somatic target cells is less well established, particularly as 
ICAM-l is only expressed at high levels on lymphoid cells and 
endothelial cells [16]. In previous reports we showed that 
ICAM-I expression is induced de novo on human renal tubular 
cells during allograft rejection, along with upregulation of MHC 
antigen expression, while there is no change in LFA-3 expres-
sion [17, 18]. Similar induction of ICAM-l has been demon-
strated during autoimmune inflammation in the mouse [19]. In 
vitro, it has been shown that ICAM-l expression can be 
induced on somatic cells by a variety of cytokines including 
interferon gamma, interleukin-l and tumor necrosis factor alpha 
[16, 20]. The cell surface expression of ICAM-l parallels in 
many respects class II MHC expression, which is also. limited 
on normal tissue but Whose expression can be induced by 
cytokines, produced by the inflammatory infiltrate [1, IS, 21]. 
The induction of such surface antigen expression can alter the 
capacity of renal tubular epitheliai cells to present antigen to 
stimulate T cells [22], but it has not been established whether 
such induction of ICAM-I by graft parenchymal cells is essen-
tial to make them vulnerable to cytotoxic T cells [1S, 23, 24]. 
In this study we examined the importance of adhesion 
molecules in determining the susceptibility of human renal 
tubular cells to lysis by alloreactive cytotoxic T cells. The 
susceptibility to lysis of cultured human kidney cells (HKC), 
which had or had not been treated with cytokines to induce 
ICAM-I and MHC expression, was compared. CDS+, HLA-A2 
specific cytotoxic T lymphocytes were used to test the relative 
importance of the various adhesion molecules by monoclonal 
antibody inhibition of cytotoxicity. Blocking either the ICAM· 
I:LFA-l or the LFA-2:LFA-3 interaction with monoclonal 
antibodies significantly reduced lysis of kidney cells to a degree 
comparable to the reduction of target cell lysis by anti-CDS or 
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Fig. 1. Surface antigen expression of 
HLA-A2 specific CTL cell line and HLA-Ar cultured human kidney cells (HKC) . 
The phenotype of CTL (_) and HKC 
cultured in the absence (D) or presence (1iliI) 
of cytokines from MLC supernatant was 
assessed by the indirect immunofluorescence 
technique and flow cytometry on a Facscan. 
Control MHC-I MHC-II LFA-l ICAM-l LFA-2 LFA-3 CD8 Al A4 A6 A. The percentage of cells staining positive; B. the mean channel immunofluorescence 
from a representative experiment. Monoclonal antibodies used for immunofluorescence 
Table 1. Monoclonal antibodies used for indirect 
immunofluorescence and inhibition of CML 
Antigen Clone References 
MHC class I HLA-ABC 17 
HLA-A2 CRI1.351 28 
MHC class II HLA-DR 29 
ICAM-I (CD54) RR1I1 30 
LFA-I (CDlla/18) TS/1.22 31 
LFA-2 (CD2) RPA-2.1O 32 
LFA-3 (CD58) TS2/9.1.1 31 
CD8 RPA-T8 33 
CD39 (B cells, Al 34 
activated T 
cells) 
CD28 (Cytotoxic A4 34 
T cells) 
CD45RO A6 34 
(Leukocyte 
common 
antigen) 
D disicodeum Irrelevant antibody 35 
(MUD-I, 
Control) 
Suppliers are: AMD, Australian Monoclonal Development, Artar-
mon, Australia; RR1I1 was a gift ofT. Springer, Blood Center, Harvard 
University Medical School, Boston; CRI1.351 was a gift of P. Parham, 
Cell Biology, Stanford; MUD-I was a gift of K. Williams, Cell Biology, 
Maquarie University, Sydney, Australia. 
anti-HLA-A2 monoclonal antibody. Further, blocking both 
leucocyte/lymphocyte adhesion ligand pairs totally abolished 
cytotoxicity. It was thus concluded that expression ofICAM-1 
by renal tubular cells during rejection might increase their 
vulnerability to damage by effector T cells. 
Methods 
Human renal tubular cells in vitro 
The culture and characterization of human kidney cells in 
vitro was as previously described [21]. For these studies HKCs 
were cultured from two tissue typed donors of the following 
HLA typing: HLA-A2+ HKC:HLA-A2, 29; HLA-B 35, 44; 
HLA-DR 4, 7 and HLA-A2- HKC:HLA-A 23, 30; HLA-B 18, 
41; HLA-DR 2, 3. Low passage number HKC were stored in 
liquid nitrogen until required, when they were thawed and 
cultured in 20% FCS (Sigma Chemical Co., St. Louis, Missouri, 
USA), in tissue culture medium consisting of Medium 199 
(Irvine Scientific, Santa Ana, California, USA) supplemented 
with glutamine (2 mM), Hepes (15 mM), Penicillin (50 ILg/ml) and 
Streptomycin (50 lLg/ml), in 75 cm2 tissue culture flasks (Corn-
ing Glass Works, Corning, New York, USA). When cell growth 
was established, usually 5 to 10 days, the tissue culture medium 
was replaced with 10% FCS until cultures approached conflu-
ence. To produce normal (uninduced) HKC targets half the 
flasks were changed to medium without FCS. The other half of 
the cultures were placed in equal volumes of 20% FCS and 
mixed lymphocyte culture supernatant (MLC SN) from day 6 
one-way allogeneic mixed lymphocyte culture (MLC), as a 
source of cytokines, in order to induce MHC and ICAM-1 
expression. HKC cultures were then further incubated until 
confluence (3 to 6 days) then removed from the plates by 
washing twice with EDTA (0.02%, Irvine Scientific) and incu-
bating with Trypsin (0.25%, Irvine Scientific) for one to two 
minutes, followed by gentle pipetting to remove cells for use 
either as target cells in cytotoxicity assays or for indirect 
immunofluorescence and flow cytometric analysis of surface 
antigen expression. This trypsin treatment is at concentrations 
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Fig. 2. Lysis of HKC or lymphocyte target cells by cytotoxic effector 
cells. HLA-A2+ induced (-.-) or uninduced (-0--), and HLA-AT 
induced (-e-) or uninduced (-0-) target eel/lysis was tested in a 
51 Cr release assay. A. HKC target cell lysis by effector T cells produced 
after 7 days in MLC with stimulators expressing HLA-A2. B. HKC 
target cell lysis by HLA-A2 specific CTL. C. Lymphocyte target cell 
lysis by HLA-A2 specific CTL. The results shown are representative 
data from 4 repeated experiments, with each data point representing at 
least 6 replicate wells. 
and times that do not significantly affect expression of the 
adhesion molecules [25]. Criteria as previously described [21] 
were used to determine that the HKC cultures were renal 
tubular cells. 
Cytotoxicity assays 
Two types of effector cells were used for cytotoxicity assays. 
First, peripheral blood lymphocytes from normal volunteers 
were used to generate allogeneic (MSvsMB) MLC effector cells 
against an HLA-A2 mismatch, in day 6 to 7 one-way bulk-
MLC, as previously described [21]. Second, well characterized 
HLA-A2 specific cytotoxic T lymphocytes (CTL) were used as 
effector cells [26, 27]. 
The tissue typing of HKC donors and peripheral blood 
lymphocyte donors was performed by the Red Cross Tissue 
Typing Laboratory, Sydney, Australia. The tissue typing of the 
peripheral blood lymphocytes used to generate effector cells in 
MLC was as follows: MS (HLA-A24, 30/31; HLA-B 35, 38; 
HLA-DR4, 7); MB (HLA-A2, 24; HLA-B 7, 60; HLA-DR 2,6). 
Target lymphocytes were HLA-A2+ (HLA-A 2, 23; HLA-B 35, 
44; HLA-DR 1, 2) or HLA-AZ- (HLA-A 24,30/31; HLA-B 35, 
51; HLA-DR 1, 5). 
Effector cells were aliquotted in 150 ILl volumes into the wells 
of disposable 96-well microtiter plates (Nunc) to achieve the 
required final effector to target ratio (E:T ratio) of 1:1, 2.5:1, 
5: 1, 10: 1, 20: 1.0r 30: 1. HKC and lymphocyte target cells were 
either HLA-A2+ or HLA-AZ-· and induced or uninduced. 
Uninduced lymphocyte target cells were freshly isolated while 
induced lymphocyte target cells were cultured with 3 lLg/ml of 
phytohemagglutinin (PHA, Sigma) for three days [23]. A cell 
pellet of 5 x 106 target cells was resuspended gently in 200 ILl of 
tissue culture medium and 250 ILCi of 51Cr (Amersham) added, 
fqllowing which the target cells were incubated for two hours at 
37°C. The targets were then washed three times before being 
resuspended at 1 x 105 cells/ml for use as target cells in CML, 
where 50 ILl was aliquotted into each well. 
Spontaneous release was determined by target cell chromium 
release in the presence of "conditioned" medium, either MLC 
supernatant or HKC culture supernatant, respectively, and 
total content was assessed directly by counting gamma emis-
sions of target cell aliquots. Experimental wells were performed 
in at least 6 replicates and spontaneous release and total content 
were the mean of 12 replicates. Following the addition of target 
cells to each well, the final volume of all wells was 200 ILl. 
The plates were immediately centrifuged for five minutes at 
300 g, and allowed to incubate at 37°C for four hours, for the 
HLA-A2 specific cytotoxic T cell effectors, or six hours for 
bulk-MLC effector cells. At the end of the lysis incubation the 
plates were again centrifuged and 100 ILl of supernatant care-
fully removed from each well, taking care to avoid the cell 
pellet. 
The specific lysis % of target cells in CML was determined 
from the mean counts by the usual formula: 
Specific lysis % 
Experimental release - spontaneous release 
Total content - spontaneous release 
x 100 
Inhibition of target cell lysis with monoclonal antibodies 
Monoclonal antibodies (Table 1) were added at a final con-
centration of 1 ILg/ml, which produced reproducible and maxi-
mal inhibition in serial dilution experiments. Inhibition of 
cytotoxicity by monoclonal antibodies was tested by the addi-
tion of 10 ILl of azide-free monoclonal antibody to at least six 
replicate wells immediately prior to the addition of target cells. 
Monoclonal antibody, which did not bind to human cells, was 
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used as a control. The inhibition of cytotoxicity assay lysis was 
calculated by the formula: 
Inhibition % 
= (1 - Mean inhibited lysis/mean control lysis) x 100 
The statistical significance of inhibition of lysis by monoclo-
nal antibodies was assessed by ANOVA using Scheffe's test for 
contrasts between gamma counts or unpaired two-tailed (-test 
comparing percentage of target cell lysis. 
Indirect immunofluorescence and flow cytometry 
The surface antigen expression of effector cells and target 
HKC was determined by indirect immunofluorescence and flow 
A1 A4 A6 
Fig. 3. Monoclonal antibody inhibition of 
HKC and lymphocyte target cell lysis by 
HLA-A2 specific CTL. Lysis (mean % of 6 
replicates ± so) of lymphocyte target cells (A) 
or HKC target cells (B, C) are shown at the 
following E:T ratios: Panel A-30:!, Panel B-
10: 1, Panel C-IO: 1. * indicates lysis 
significantly less than lysis with control or no 
monoclonal antibody (N = 6, P < 0.05, 
ANOVA and Scheffe's test). Results of one 
representative experiment, of 4 similar 
experiments, are shown. 
cytometry [21]. Briefly, HKC were washed in phosphate buff-
ered saline (PBS) following trypsinization, and resuspended in 
Medium 199 and 10% human A serum. Mouse monoclonal 
antibody (5 to 10 ILl) was added to 50 ILl aliquots of cells and 
incubated for 30 minutes on ice, following which cells were 
washed twice in PBS and 50 ml of sheep-anti-mouse FITC 
conjugate (Caltag Labs, San Francisco, California, USA) added 
with 20 ILl of human A serum for 30 minutes on ice. Finally, 
cells were washed twice and analyzed on a Facscan (Becton 
Dickinson, Mountain View, California, USA), with appropriate 
gating set by the use of a control monoclonal antibody. The 
number of cells positive for immunofluorescence, expressed as 
a percentage, and the mean channel immunofluorescence, an 
index of staining intensity expressed as a logarithmic scale in 
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Fig. 4. Comparison between induced and uninduced HKC or mono-
clonal antibody inhibition of lysis by HLA-A2 specific CTL. The 
inhibitory effect on cytotoxicity (mean % :!: SD, N = 8) of the addition 
of specific antibody, as compared to control antibody, is shown for 
induced (.) and uninduced (riill) HLA-A2+ HKC target cell lysis. 
arbitrary units, were read out. Comparisons were made using 
unpaired two-tailed (-tests. 
Results 
Expression of surface antigens by human kidney cells and 
HLA-A2 specific cytotoxic T lymphocytes 
Expression of cell surface antigens by HLA-A2 specific CTL 
and by HKC target cells was determined by indirect immuno-
fluorescence and flow cytometric analysis in eight experiments, 
and the percentage positive staining and mean channel immu-
nofluorescence results of a representative experiment are 
shown in Figure 1. The HLA-A2 specific CTL were positive for 
MHC class I, CD8, LFA-2 (CD2) and LFA-l. Fifty-one percent 
of these effector T cells were positive for MHC class II but only 
14% were positive forICAM-I, while LFA-3 was expressed at 
low levels with only 7% of CTL staining positive. While the 
majority of effectors expressed activation markers Al and A6, 
none expressed A4. 
HKC did not express LFA-l, LFA-2 (CD2), CD8, AI, A4 or 
A6. Both induced and uninduced HKC expressed MHC class I 
antigens. The expression of MHC class II by uninduced HKC 
remained near background (~5%), whereas ICAM -I expression 
was high (73% positive), unlike renal tubular cells in vivo. 
ICAM-l expression varied from culture to culture probably 
because of differences in the FCS in the media, and the results 
presented are different from our previous report [17]. Only 44% 
of uninduced HKC stained positively for LFA-3. 
The addition of cytokines during culture resulted in a signif-
icant increase in HKC expression of MHC class I, MHC class 
II and ICAM-I but no change in LFA-I or LFA-3. As the 
majority of uninduced HKC already expressed MHC class I in 
vitro there was no increase in the percentage of cells positive 
for MHC class I staining following induction. The upregulation 
of MHC class I antigen was best demonstrated by a change in 
the mean channel of immunofluorescence, reflecting the num-
ber of antibodies binding each cell, which increased from 78 ± 
22 (SD) to 134 ± 58 units (N = 8, P = 0.021, unpaired two tailed 
t-test). Parallel changes were seen in HKC from the HLA-A2+ 
donor examined for HLA-A2 expression, where the mean 
channel immunofluorescence increased from 98 ± 30 to 217 ± 
127 units (N = 5, P = 0.044). Cytokine induction resulted in an 
increase in percentage of HKC staining positive for MHC class 
II from 5.4% to 17.1% (N = 8, P = 0.013) and for ICAM-I from 
73.5% to 90.4% (N == 8, P = 0.004). The mean channel 
immunofluorescence for MHC class II antigen increased signif-
icantly from 71 ± 37 to 88 ± 75 units, while the mean channel 
immunofluorescence for ICAM-I also increased from 104 ± 45 
to 146 ± 95 units. Thus, cultured HKC express high levels of 
class I MHC and ICAM-l and after induction with cytokines 
expression of these molecules, as well as of class II MHC, is 
further upregulated. 
Lysis of target cells 
The lysis of HKC target cells by HLA-A2 specific CTL (N = 
4) and by days 6 to 7 unfractionated MLC effector cells (N = 4) 
was examined (Fig. 2), and the results compared to the lysis of 
lymphocyte target cells by HLA-A2 specific CTL (N == 4). The 
lysis of the irrelevant HLA-A2- target cells was always much 
lower than the lysis of HLA-A2+ target cells, and no further 
results using HLA-A2- target cells are therefore presented. 
Induced HKC target cells consistently showed a greater 
target cell susceptibility to lysis than uninduced HKC target 
cells. These results suggest that induction of MHC antigen and 
ICAM -1 expression contributed to the increased target cell 
susceptibility to lysis found in induced HKC target cells. For 
this reason the relative importance of these antigens to HKC 
target cell lysis in cytotoxic assays was examined using mono-
clonal antibodies to block specific ligands. In all subsequent 
experiments MLC effector cells and HLA-A2 specific CTL 
were compared, but as there was no difference only data on the 
latter is presented. 
Inhibition of HKC target cell lysis by monoclonal antibodies 
The ability of monoclonal antibodies to inhibit the lysis of 
HKC target cells and lymphocyte target cells, which were 
either induced or uninduced, was examined in cytotoxicity 
assays (Fig. 3), and the pattern of inhibition was similar to both 
MLC and specific CTL effector cell popUlations. Monoclonal 
antibodies against CD2, CD8, ICAM-l and LFA-l invariably 
produced significant inhibition of both lymphocyte and HKC 
target cell lysis. Monoclonal antibody against LFA-3, however, 
showed its clearest inhibitory effects in experiments using 
lymphocyte target cells, while its blocking effect against HKC 
target cell lysis was intermediate (Figs. 3 and 5). The pattern of 
monoclonal antibody inhibition of cytotoxicity was similar for 
both HLA-A2+ and HLA-A2- HKC target cells, although 
HLA-A2- HKC target cells were lysed to a much lower degree 
(data not shown). Monoclonal antibodies to activation antigens 
(AI, A4 and A6), which bound the effector cells but not the 
target cells, did not result in inhibition of target cell lysis, except 
that A6 weakly inhibited HKC target cell lysis (approximately 
20% inhibition). These results show that the binding of mono-
clonal antibodies to effector cells did not have a non-specific 
inhibitory effect. 
Despite the differences in surface antigen expression between 
induced and uninduced HKC target cells, which resulted in 
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monoclonal antibodies on the inhibition of 
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monoclonal antibodies, at maximal inhibiting 
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different susceptibility to lysis, the relative inhibition oflysis by 
saturating amounts of monoclonal antibody was similar (Fig. 4). 
As no single monoclonal antibody at concentrations which 
produced maximal blocking completely inhibited lysis, we 
examined whether there was synergy between monoclonal 
antibodies (Fig. 5). LFA-l and ICAM-l antibodies alone had a 
similar inhibitory effect, which was not additive. The inhibition 
of lysis by antibody against LF A-2 (CD2) and LF A-3 was also 
comparable, but the two together were no more potent than 
either alone. This confirmed that maximal inhibition of a single 
ligand pair was not sufficient to totally abrogate lysis. The 
combination of LFA-I and LFA-2 antibodies, however, pro-
duced almost complete inhibition of HKC target cell lysis by 
HLA-A2 specific CTL (Fig. SA). This indicates that the two 
leukocyte-lymphocyte adhesion pathways are complementary. 
The addition of monoclonal antibody against HLA-A2 or 
CD8 also inhibited cytotoxicity (Fig. 5B). While the former 
blocks T cell receptor recognition of the allospecific regions of 
class I MHC, the monoclonal antibody to CD8 blocks its 
interaction with the invariant alpha-3 domain of class I MHC 
molecule [36]. There was synergy between anti-HLA-A2 anti-
body and antibody to CD8 or LFA-2 (Fig. 5B), which resulted 
in almost complete inhibition of lysis and was comparable to 
that of blocking both LFA-I and LFA-2. 
Discussion 
In this study the importance of both the ICAM-] :LF A-I and 
LFA-2:LFA-3 leucocyte/lymphocyte adhesion interactions in 
class I-restricted CD8+ cytotoxic T cell-mediated lysis of 
human kidney cells was established. Cultured human kidney 
cells, which were shown to be predominantly renal tubular cells 
by previously established criteria [21], were used as target cells 
in in vitro cytotoxicity assays. HKC target cells were killed by 
CTL specific for HLA-A2, or cytotoxic T cells generated in a 
mixed lymphocyte culture. Uninduced, in vitro cultured renal 
tubular cells expressed class I MHC, ICAM-I and LFA-3, 
unlike these cells in vivo, where expression of class I MHC is 
low and class II MHC and ICAM-I is undetectable [17]. Culture 
of kidney cells with cytokines in vitro increased expression of 
MHC class I and MHC class II antigens and increased the 
expression of ICAM-I, but not LFA-3, much the same as 
occurs in vivo with renal allograft rejection [17, 18, 21, 37]. 
These induced HKC targets were more susceptible to lysis in in 
vitro cytotoxicity assays, by both HLA-A2 specific CTL and 
MLC effector cells. Together these studies suggested that the 
increased expression of these molecules may increase target 
cell susceptibility to lysis [23] . 
The importance of the leucocyte-lymphocyte adhesion mol-
ecules in the mediation of cytotoxicity was directly established 
by addition of monoclonal antibodies known to inhibit adhesion 
between T cells and lymphocyte target cells. In these experi-
ments monoclonal antibodies, at saturating concentrations, 
against anyone of ICAM-I, LFA-I, LFA-2 or LFA-3 signifi-
cantly inhibited lysis of kidney cells by either HLA-A2 specific 
CTL or MLC effector cells. The degree of inhibition was similar 
to their effect on the lysis of lymphocyte target cells, and was 
comparable to blocking the CD8 molecule or the HLA-A2 MHC 
class I molecule. Although the lysis of HLA-A2- target cells, 
by HLA-A2 specific CTL or MLC effector cells, was much less 
than the lysis of HLA-A2+ target cells, in both cases target cell 
lysis was inhibited by antibodies to a similar degree, suggesting 
that the susceptibility to lysis of irrelevant target cells relies on 
a contribution by antigen non-specific accessory adhesion 
bridges. The blocking effects of these monoclonal antibodies 
was specific, however, as addition of irrelevant monoclonal 
antibodies had no effect. 
An indication that the two leucocyte-lymphocyte adhesion 
pathways complement each other was the finding of synergy 
between antibodies blocking non-complementary molecules , 
but not between those blocking the same adhesion pathway. 
These results show that the leucocyte-lymphocyte adhesion 
molecule interactions help mediate effector T cell killing of 
kidney cells, and that blocking of both adhesion interactions 
can totally abrogate killing. Blocking the T cell receptor-
mediated specific binding to HLA-A2, required for activation of 
cytotoxicity, was achieved by a combination of antibodies 
against HLA-A2 and against CD8. This completely inhibited 
lysis of HKC target cells, as did the combination of antibodies 
against LF A-I and LF A-2. This indicated that both antigen 
non-specific conjugate formation and specific binding of the T 
cell receptor to class I MHC are essential steps in the lysis of 
HKC target cells. 
As the effector cells expressed high levels of LFA-I but low 
levels of ICAM-I and LFA-3 and the HKC target cells did not 
express LFA-I or LFA-2, the inhibition due to the addition of 
antibody against ICAM-I must have acted at the target cell 
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level, thus strongly supporting the importance of ICAM-I 
expression on HKC in determining susceptibility to lysis. While 
much evidence shows that these antibodies to adhesion ligands 
inhibit lysis by preventing adhesion [14, 15], antibody binding to 
LF A-I and LFA-2 can also result in the transduction of signals 
regulating T cell activation [38-40]. The studies presented here, 
however, do not address these issues. 
The significant role of ICAM-I in HKC lysis in vitro has 
important implications for the role of ICAM-J in vivo in renal 
allograft rejection. ICAM-l, which is absent on resting renal 
tubular cells in vivo, is readily induced by cytokines produced 
by activated T cells. This may be an important factor in 
determining renal tubular cell susceptibility to lysis in cell-
mediated renal allograft rejection. The results of this study 
support the use of antirejection therapy targeted at the ICAM-l 
molecule [41, 42]. It may also be possible to inhibit the 
upregulation ofICAM-l to prevent its contribution to increased 
allograft susceptibility to damage by cell mediated cytotoxicity. 
While normal kidney tubular cells have low or no constitutive 
expression of ICAM-l and MHC antigens, and therefore may 
be relatively protected from cytotoxic T cells, other cells in the 
kidney, especially vascular endothelium, have a high constitu-
tive expression of these molecules and therefore may be very 
susceptible to lysis by effector T cells without prior upregula-
tion of cell surface molecule expression. This is consistent with 
the vasculature, including capillaries, being a primary target of 
rejection [43]. 
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